THERE have been few fundamental contributions to the diagnosis and management of biliary-tract disease in recent years, but a current evaluation of the subject is justified in view of the large num ...

Medically reviewed by Jay N. Yepuri, MD Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the ...

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...

“djuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive tract diseases, positioning these molecules as potential biomarkers for ...

Oncology/Hematology > Other Cancers FDA Approves Zanidatamab for Biliary Tract Cancer — New antibody indicated for previously treated, unresectable or metastatic HER2-positive disease ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best high short interest stocks with huge upside potential. On July 2, Jazz ...

Olaparib demonstrated activity in a phase 2 trial of patients who had advanced biliary tract cancer with homologous recombination repair (HRR) mutations. Results from this trial were presented at the ...

Potential Positives. Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China, addressing a significant unmet medical need in this ...